Search the Newsreel

Immunic (IMUX) Earnings Date and Reports 2026

Immunic (IMUX) announced its Q2 2026 earnings on August 11, 2026, reporting an EPS of -$0.80, which surpassed analysts' consensus estimates of -$1.16 by $0.36. The company's earnings are projected to improve from -$4.41 to -$4.05 per share next year. The article provides detailed …

BMNR Stock Alert: Is Bitmine Immersion The New MicroStrategy? Lantern Fly (k3rlQoZskN)

Form 8K Immunic Inc For: 11 August By Investing.com

The article is a brief announcement indicating that Immunic Inc. filed a Form 8K on August 11. It mentions the company's stock symbol IMUX and its price performance, but provides no further details about the content of the filing. The rest of the page …

Shimmick (SHIM) Stock Price Drops As Margin Recovery Meets Cash Strain

Lyell Immunopharma COO Stephen J. Hill Sells Shares to Cover Tax Withholding on RSU Settlement

Stephen J. Hill, the Chief Operating Officer of Lyell Immunopharma, Inc., conducted an automatic share sale on August 10, 2026. This transaction was carried out to cover tax obligations stemming from the settlement of his vested restricted stock units. The sale was reported in …

Immunome Q2 Results: EPS Misses Estimate, Losses Widen 30% YoY

Immunome Inc. reported a Q2 2026 net loss of $73.1 million, significantly wider than the previous year, primarily due to increased R&D and administrative expenses, and missed EPS estimates. Despite financial challenges, the company secured FDA acceptance for its varegacestat NDA with a PDUFA …

Estrella adds fourth site to EB103 lymphoma trial

Estrella Immunopharma Inc. has activated a fourth clinical site, University Hospitals Cleveland Medical Center, for its STARLIGHT-1 Phase I/II trial of EB103, an investigational T-cell therapy for B-cell non-Hodgkin's lymphoma. This expansion aims to evaluate the therapy's safety and efficacy, with data expected to …

Lyell Immunopharma VP Bulis sells $8,905 of common stock

Veronica Sanchez Bulis, VP at Lyell Immunopharma (NASDAQ:LYEL), sold 621 shares for $8,905 to cover tax obligations from vested restricted stock units. The company's stock has been volatile, down 53% YTD, but holds more cash than debt despite burning through cash quickly. Lyell also …

Immunome (IMNM) widens losses as it funds oncology pipeline with $520M cash

Altimmune (ALT) Q2 Earnings Preview: Unpacking Valuation and Gur

Altimmune (ALT) Q2 Earnings Preview: Unpacking Valuation and Guru Ownership Signals

Lyell Immunopharma (LYEL) CEO sells shares to cover RSU tax withholding

Lyell Immunopharma's President and CEO, Lynn Seely, automatically sold 390 shares of common stock on August 10, 2026. This transaction was conducted to cover tax withholding obligations associated with vested restricted stock units. The shares were sold at a weighted average price of $14.34 …

Lyell Immunopharma (LYEL) VP auto-sells 621 shares to cover RSU taxes

Veronica Sanchez Bulis, VP and Corporate Controller at Lyell Immunopharma (LYEL), automatically sold 621 shares of common stock on August 10, 2026, at a weighted average price of $14.34 per share. This sale was conducted to cover tax withholding obligations associated with the settlement …

Immunome (NASDAQ:IMNM) Releases Quarterly Earnings Results, Misses Estimates By $0.14 EPS

Immunome (NASDAQ:IMNM) announced its quarterly earnings, reporting a loss of $0.65 per share, which missed the consensus estimate by $0.14. Despite the earnings miss, the stock rose by $0.56 to $26.25, and analysts largely maintain a "Moderate Buy" rating with a $34.18 average price …

AC Immune (ACIU) FDA Approvals, PDUFA Dates & Drug Alerts 2026

This article provides an overview of AC Immune's drug pipeline and recent FDA-related milestones for several of its investigational therapies. It details regulatory events such as Fast Track designations, interim clinical trial data, and publication updates for drugs targeting Parkinson's disease, Alzheimer's disease, and …

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 5.3% - Time to Sell?

Immunic (NASDAQ:IMUX) Issues Quarterly Earnings Results, Beats Estimates By $0.36 EPS

Immunic (NASDAQ:IMUX) reported its quarterly earnings, beating analyst estimates by $0.36 EPS with a reported ($0.80) earnings per share. The company's stock opened at $14.62, with a market capitalization of approximately $199 million, and has seen significant institutional investment. Wall Street analysts maintain a …

Immunocore Holdings plc (IMCR) Stock Analysis: Uncovering an 87% Upside Potential in Biotechnology

Immunocore Holdings plc (IMCR) is a UK-based biotechnology firm with a market capitalization of $1.73 billion, attracting investor attention due to an estimated 87.27% upside potential. This growth is driven by its innovative pipeline of immunomodulating medicines for cancer, infectious, and autoimmune diseases, and …

Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma has announced the activation of University Hospitals Cleveland Medical Center as the fourth clinical site for its STARLIGHT-1 Phase I/II clinical trial. This trial is evaluating EB103, an ARTEMIS® T-cell therapy targeting CD19, for patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. …

Estrella adds fourth site to EB103 lymphoma trial By Investing.com

Estrella Immunopharma Inc. (NASDAQ:ESLA) has activated a fourth clinical site, University Hospitals Cleveland Medical Center, for its STARLIGHT-1 Phase I/II trial of EB103. This trial evaluates EB103, a CD19-redirected T-cell therapy, for patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. The company anticipates using …

Immunotech Biopharm Sets August Board Meeting to Approve Interim Results

HC Wainwright Estimates Immix Biopharma FY2027 Earnings

HC Wainwright forecasts Immix Biopharma (NASDAQ: IMMX) to report a loss of $0.20 per share for FY2027, maintaining a "Buy" rating and a $25 price target. This contrasts with the current consensus estimate of a $0.69 loss per share. The company recently reported a …

Immunic advances MS drug toward key Phase 3 data, expects results by year-end

Immunic advances MS drug toward key Phase 3 data, expects results by year-end Proactive uses images sourced from Shutterstock Immunic Inc (NASDAQ:IMUX, FRA:10VA) is preparing for a series of clinical and corporate milestones as it advances its lead drug candidate vidofludimus calcium through late-stage …

Analysts Offer Predictions for AC Immune FY2026 Earnings

AC Immune Secures FDA Fast Track For ACI-7104 In Parkinson's; Stock Up

(RTTNews) - AC Immune SA (ACIU) announced that the FDA has granted Fast Track designation to ACI-7104, its anti-alpha-synuclein active immunotherapy for the treatment of early Parkinson's disease. Parkinson's disease is a progressive neurodegenerative disorder affecting movement and quality of life. Alpha-synuclein proteins are …

Immunic Inc (IMUX) Q2 Earnings Beat Highlights Growth Potential Despite Unprofitability

AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)

AC Immune SA announced that its anti-alpha-synuclein active immunotherapy candidate, ACI-7104, has received FDA Fast Track designation and IND clearance for treating early Parkinson's disease (PD). The designation acknowledges the potential of ACI-7104 to address significant unmet needs in PD, based on positive interim …

AC Immune’s Parkinson’s Candidate Shows 100% Responder Rate

AC Immune (NASDAQ: ACIU) has received FDA Fast Track designation and IND clearance for ACI-7104, its anti-alpha-synuclein active immunotherapy, to treat early Parkinson’s disease. Interim Phase 2 data at 76 weeks showed ACI-7104 was safe, well-tolerated, and achieved a 100% immunogenicity responder rate. The …

AC Immune (NASDAQ: ACIU) gains FDA Fast Track, IND clearance for Parkinson’s drug ACI-7104

AC Immune (NASDAQ: ACIU) announced that its anti-alpha-synuclein active immunotherapy, ACI-7104, received FDA Fast Track designation and IND clearance for early-stage Parkinson’s disease. This designation facilitates development and regulatory review for ACI-7104, which showed promising interim Phase 2 results for safety, tolerability, and immunogenicity. …

AC Immune receives FDA fast track status for parkinson’s drug

AC Immune SA announced that the FDA granted Fast Track designation and cleared its Investigational New Drug application for ACI-7104, an anti-alpha-synuclein active immunotherapy for early-stage Parkinson’s disease. This designation is based on positive interim Phase 2 data from the VacSYn trial, showing the …

Immix Biopharma publishes corporate presentation on NXC-201 BCMA CAR-T in relapsed/refractory AL amyloidosis

Immix Biopharma has published a corporate presentation detailing its lead program, NXC-201 BCMA CAR-T, for relapsed or refractory AL amyloidosis. The presentation highlights a 95% complete response rate for NXC-201 from its NEXICART-2 U.S. phase 1/2 trial, which has completed enrollment with 45 patients. …

Immunic CEO on Q2 progress and Phase 3 MS trial milestones

Immunic CEO Erik Lundgren discussed the company's Q2 results, leadership changes, and key milestones for its multiple sclerosis (MS) program. The company's two Phase 3 studies for relapsing MS are fully enrolled and expected to report results by year-end, with Immunic also planning to …

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Immix Biopharma, Inc. Stock 12‑Month Price Target Cut to $20.44, Implies 102% Upside

Immix Biopharma, Inc. (IMMX) has seen its average 12-month price target adjusted down slightly from $20.56 to $20.44 by 8 analysts. Despite the minor cut, the new target still implies a significant 102% potential upside from its Aug. 10 closing price. The consensus rating …

TAG Immobilien Q2 Earnings Call Highlights

Key Points Interested in TAG Immobilien AG? Here are five stocks we like better. Strong first-half performance: FFO I rose 9% year over year to €100.2 million, prompting TAG to expect full-year FFO I near the upper end of guidance at approximately €197 million. …

Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating

Morgan Stanley has adjusted its price target for Immix Biopharma (IMMX) to $19, down from $20, while maintaining an Overweight rating on the stock. This update comes after the company recently reported its earnings results for the second quarter and six months ended June …